# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001731122-25-000607
Filing Date
2025-04-25
Accepted
2025-04-25 16:31:01
Documents
7
Period of Report
2025-04-25

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM DEF 14A | e6511_def14a.htm | DEF 14A | 403248
2 | GRAPHIC | image_001.gif | GRAPHIC | 7571
3 | GRAPHIC | image_002.gif | GRAPHIC | 6119
4 | GRAPHIC | image_003.gif | GRAPHIC | 306
5 | GRAPHIC | image_004.gif | GRAPHIC | 6141
6 | GRAPHIC | p_001.jpg | GRAPHIC | 1709075
7 | GRAPHIC | p_002.jpg | GRAPHIC | 1318180
| Complete submission text file | 0001731122-25-000607.txt |  | 4589949

Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37606 | Film No.: 25874610
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)